Effect of human umbilical cord blood mesenchymal stem cell transplantation on neuronal metabolites in ischemic rabbits

BMC Neuroscience

Qing-Song Wang³  You-Zi Zhu²  Bo Liu¹  Zhi-Wei Wang³  Hai-Li Huang³  Xue-Chun Liu³  Yao Zhu³  Ye-Ming Guan³ 

[1] Center for Cell Therapy, The 105th Hospital of PLA, Clinic College, Anhui Medical University, Hefei 230031, China;Department of Radiology, The 105th Hospital of PLA, Clinic College, Anhui Medical University, Hefei 230031, China;Department of Neurology, The 105th Hospital of PLA, Clinic College, Anhui Medical University, Hefei 230031, China

关键词: Middle cerebral artery occlusion;    Proton magnetic resonance spectroscopy;    Cerebral ischemia;    Human umbilical cord blood mesenchymal stem cells;   

Others  :  799435
DOI  :  10.1186/1471-2202-15-41

 received in 2013-07-15, accepted in 2014-03-12,  发布年份 2014

【 摘 要 】

Background

Because there is little research on the effects of transplanted stem cells on neuronal metabolites in infarct areas, we transplanted human umbilical cord blood mesenchymal stem cells (hUCB-MSCs) into cerebral ischemic rabbits and examined the neuronal metabolites.

Results

Rabbits (n = 40) were equally divided into sham, middle cerebral artery occlusion (MCAO), hUCB-MSC, and saline groups. The rabbit ischemic model was established by MCAO. The effects of hUCB-MSC transplantation were assessed by proton magnetic resonance spectroscopy (¹H-MRS), neurological severity scores (NSSs), infarct area volume, neuronal density, and optical density (OD) of microtubule-associated protein 2 (MAP2)-positive cells. We also evaluated complete blood cell counts(CBCs) and serum biochemical parameters. NSSs in the hUCB-MSC group at 7 and 14 days after reperfusion were lower than in MCAO and saline groups (p < 0.05). Compared with MCAO and saline groups at 2 weeks after MCAO, the infarction volume in the hUCB-MSC group had decreased remarkably (p < 0.05). Significant neuronal metabolic changes occurred in the infarct area at 24 h and 2 weeks after MCAO. ¹H-MRS revealed an elevation in the lactate (Lac)/creatine including phosphocreatine (Cr) ratio and a decrease in the N-acetylaspartate (NAA)/Cr and choline-containing phospholipids (Cho)/Cr ratios at 24 h after MCAO in the MCAO group (p < 0.01). Compared with saline and MCAO groups at 24 h and 2 weeks after MCAO, NAA/Cr and Cho/Cr ratios had increased significantly, whereas the Lac/Cr ratio had decreased significantly in the hUCB-MSC group (p < 0.01). Neuronal density and OD of MAP2-positive cells in the MCAO group were significantly lower than those in the sham group, whereas the neuronal density and OD of MAP2-positive cells in the hUCB-MSC group were higher than those in MCAO and saline groups (p < 0.05). CBCs and biochemical parameters were unchanged in the MCAO group at 24 h and 2 weeks after hUCB-MSC transplantation.

Conclusions

Transplanted hUCB-MSCs might ameliorate ischemic damage by influencing neuronal metabolites in the infarct area, providing additional evidence for neuroprotection by stem cells. No significant changes were observed in CBCs or serum biochemical parameters, suggesting that intravenous infusion of hUCB-MSCs is safe for rabbits in the short-term.

【 授权许可】

   
2014 Guan et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

Figure 6.

Figure 7.

Figure 8.

Figure 9.

Figure 10.

Figure 11.

Figure 12.

Figure 13.

【 参考文献 】

• [1]Yang G, Wang Y, Zeng Y, Gao GF, Liang X, Zhou M, Wan X, Yu S, Jiang Y, Naghavi M, Vos T, Wang H, Lopez AD, Murry CJ: Rapid health transition in China, 1990–2010: findings from the global burden of disease study 2010. Lancet 2013, 381:1987-2015.
• [2]Burns TC, Verfaillie CM, Low WC: Stem cells for ischemic brain injury: a critical review. J Comp Neurol 2009, 515:125-144.
• [3]Banerjee S, Williamson DA, Habib N, Chataway J: The potential benefit of stem cell therapy after stroke: an update. Vasc Health Risk Manag 2012, 8:569-580.
• [4]Lim JY, Jeong CH, Jun JA, Kim SM, Ryu CH, Hou Y, Oh W, Chang JW, Jeun SS: Therapeutic effects of human umbilical cord blood-derived mesenchymal stem cells after intrathecal administration by lumbar puncture in a rat model of cerebral ischemia. Stem Cell Res Ther 2011, 2:38-51.
• [5]Chen J, Li Y, Wang L, Lu M, Zhang X, Chopp M: Therapeutic benefit of intravenous administration of bone marrow stromal cells after cerebral ischemia in rats. Stroke 2001, 32:1005-1011.
• [6]Bacigaluppi M, Pluchino S, Jametti LP, Kilic E, Kilic U, Salani G, Brambilla E, West MJ, Comi G, Martino G, Hermann DM: Delayed post-ischaemic neuroprotection followingsystemic neural stem cell transplantation involvesmultiple mechanisms. Brain 2009, 132:2239-2251.
• [7]Harada K, Honmoua O, Liua H, Bandob M, Houkina K, Kocsisc JD: Magnetic resonance lactate and lipid signals in rat brain after middle cerebral artery occlusion model. Brain Res 2007, 1134:206-213.
• [8]Kenshi T, Hironaka I, Masaki H, Hitoshi M, Masatoyo N, Tsutomu N: Serial assessments of delayed encephalopathy after carbon monoxide poisoning using magnetic resonance spectroscopy and diffusion tensor imaging 3.0 T system. Eur Neurol 2008, 59:55-61.
• [9]Caplan AI: Mesenchymal stem cells. J Orthop Res 1991, 9:641-650.
• [10]Lee J, Kuroda S, Shichinohe H, Ikeda J, Seki T, Hida K, Tada M, Sawada K, Iwasaki Y: Migration and differentiation of nuclear fluorescence-labeled bone marrow stromal cells after transplantation into cerebral infarct and spinal cord injury in mice. Neuropathology 2003, 23:169-180.
• [11]Keating A: Mesenchymal stromal cells. Curr Opin Hematol 2006, 13:419-425.
• [12]Shichinohe H, Kuroda S, Yano S, Ohnishi T, Tamagami H, Hida K, Iwasaki Y: Improved expression of gamma-aminobutyric acid receptor in mice with cerebral infarct and transplanted bone marrow stromal cells: an autoradiographic and histologic analysis. J Nucl Med 2006, 47:486-491.
• [13]Bang OY, Lee JS, Lee PH, LEE G: Autologous mesenchymal stem cell transplantation in stroke patients. Ann Neurol 2005, 57:874-882.
• [14]Lindvall O, Kokaia Z, Martinez-Serrano A: Stem cell therapy for human neurodegenerative disorders-how to make it work. Nat Med 2004, 10:42-50.
• [15]Jeong JA, Hong SH, Gang EJ, Ahn C, Hwang SH, Yang IH, Han H, Kim H: Differential gene expression profiling of human umbilical cord blood derived mesenchymal stem cells by DNA microarray. Stem Cells 2005, 23:584-593.
• [16]Iihoshi S, Honmou O, Houkin K, Hashi K, Kocsis JD: A therapeutic window for intravenous administration of autologous bone marrow after cerebral ischemia in adult rats. Brain Res 2004, 1007:1-9.
• [17]Kurozumi K, Nakamura K, Tamiya T, Kawano Y, Kobune M, Hirai S, Uchida H, Sasaki K, Ito Y, Kato K, Honmou O, Houkin K, Date I, Hamada H: BDNF gene-modified mesenchymal stem cells promote functional recovery and reduce infarct size in the rat middle cerebral artery occlusion model. Mol Ther 2004, 9:189-197.
• [18]Li Y, Chen J, Chen XG, Wang L, Gautam SC, Xu YX, Katakowski M, Zhang LJ, Lu M, Janakiraman N, Chopp M: Human marrow stromal cell therapy for stroke in rat: neurotrophins and functional recovery. Neurology 2002, 59:514-523.
• [19]Wang Q, Guan Y, Liu X, Liu H, Wang J: The free radical scavenger, edaravone, ameliorates delayed neuropsychological sequelae after acute carbon monoxide poisoning in rabbits. Undersea Hyperbaric Med 2013, 40:219-225.
• [20]Abe K, Yoshimura H, Tanaka H, Fujita N, Hikita T, Sakoda S: Comparison of conventional and diffusion weighted MRI and proton MR spectroscopy in patients with mitochondrial encephalomyopathy, lactic acidosis, and stroke-like events. Neuroradiology 2004, 46:113-117.
• [21]Honmaa T, Honmou O, Iihoshia S, Haradaa K, Houkina K, Hamadab H, Kocsis JD: Intravenous infusion of immortalized human mesenchymal stem cells protects against injury in a cerebral ischemia model in adult rat. Exp Neurol 2006, 199:56-66.
• [22]Janowski M, Walczak P, Date I: Intravenous route of cell delivery for treatment of neurological disorders: a meta-analysis of preclinical results. Stem Cells Dev 2010, 19:5-16.
• [23]Burns TC, Steinberg GK: Stem cells and stroke: opportunities, challenges, and strategies. Expert Opin Biol Ther 2011, 11:447-461.
• [24]Stem Cell Therapies as an Emerging Paradigm in Stroke participants: Stem Cell Therapies as an Emerging Paradigm in Stroke (STEPS): bridging basic and clinical science for cellular and neurogenic factor therapy in treating stroke. Stroke 2009, 40:510-515.
• [25]Aronowski J, Strong R, Grotta JC: Reperfusion injury: demonstration of brain damage produced by reperfusion after transient focal ischemia in rats. J Cereb Blood Flow Metab 1997, 17:1048-1056.
• [26]Yang SE, Ha CW, Jung M, Jin HJ, Lee M, Song H, Choi S, Oh W, Yang YS: Mesenchymal stem/progenitor cells developed in cultures from UC blood. Cytotherapy 2004, 6:476-486.
• [27]Luo G, Cheng W, He W, Wang X, Tan J, Fitzgerald M, Li X, Wu J: Promotion of cutaneous wound healing by local application of mesenchymal stem cells derived from human umbilical cord blood. Wound Rep Reg 2010, 18:506-513.
• [28]Purdy PD, Devous MD, Batjer HH, White CL, Meyer Y, Samson DS: Microfibrillar collagen model of canine cerebral infarction. Stroke 1989, 20:1361-1367.
• [29]Kondziella D, Danielsen ER, Hansen K, Thomsen C, Jansen EC, Arlien-Soeborg P: H1– MR spectroscopy of gray and white matter in carbon monoxide poisoning. J Neurol 2009, 256:970-979.
• [30]Feng HL, Yan L, Cui LY: Effects of repetitive transcranial magnetic stimulation on adenosine triphosphate content and microtubule associated protein-2 expression after cerebral ischemia-reperfusion injury in rat brain. Chin Med J 2008, 121:1307-1312.